Clinical trial
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total…
NCT00093028 · University of Arkansas, Other · Completed
Key facts
| NCT number | NCT00093028 |
|---|---|
| Title | Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II |
| Official title | UARK 2003-35, A Phase III Study of Bortezomib Versus Bortezomib in Two Doses in Combination With Revlimid™ for Patients Relapsing or Progressing on Total Therapy II (UARK 98-026) |
| Lead sponsor | University of Arkansas, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | CC-5013 (Revlimid™), bortezomib |
| Enrollment | 315 |
| Start date | Jan 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Oct 1, 2004 |
| Last update posted | Jul 2, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: